Is ACEI superior to ARB for CKD?

Internal Medicine

Volumn 45, Issue 4, 2006, Pages 179-181

  Imai, Enyu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BRADYKININ; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LOSARTAN; TRANDOLAPRIL; VALSARTAN;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; EDITORIAL; HUMAN; HYPERTENSION; KIDNEY FAILURE; PRACTICE GUIDELINE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; RENAL INSUFFICIENCY;

EID: 33645017493     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.45.0141     Document Type: Editorial

References (14)

1. Wier MR, Henrich WL. Theoretyical basis and clinical evidence for different effects of angiotensin-converting inhibitors and angiotensin II receptor subtypr 1 blockers. Curr Opin Nephrol Hypertension 9: 403-411, 2000.
2. Taal MW, Brenner BM. Combination ACEI and ARB therapy: additional benefit in renoprotection. Curr Opin Hypert Nephrol 11: 377-381, 2002.
3. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67: 799-812, 2005.
4. Shoda J, Kanno Y, Suzuki H. A five year comparison of the renal protective effects of angiotensin converting inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern Med 45: 193-198, 2006.
5. Gainer JL, Morrow J, Loveland A, King D, Brown N. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339: 1285-1292, 1998.
6. Chan JC, Wat NM, So WY et al. Renin angiotensin aldosteron system blockade and renaldisease in patients with type 2 diabetes. An Asian perspective from RENAAL study. Diabetes Care 27: 874-879, 2004.
7. Mogensen C, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440-1444, 2000.
8. Nakao N, Yoshimura A, Morita H, Takeda M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease. (COOPERATE): a randomised controlled trial. Lancet 361, 2003.
9. Gansevoort R, de Zeeuw D, de Jong P. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 45: 861-867, 1994.
10. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibitor and angiotensin II receptor blockade. J Hypertens 20:125-130,2002.
11. Russo D, Minutolo, R, Pisani A, et al. Coadministration of losartan and enarapril exrets additive antiproteinuric effects in IgA nephropathy. Am J Kidney Disease 38: 18-25, 2001.
12. Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatement in human chronic nephriitis. Kidney Int 63: 1094-1103, 2003.
13. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enarapril on kidney function in hypertensive type 2 diabetes with early nephropathy. Kidney Int 58: 762-769, 2000.
14. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibiton in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961, 2004.